-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer (BC) is one of the most commonly diagnosed cancers, which seriously affects women's health.
Breast cancer (BC) is one of the most commonly diagnosed cancers, which seriously affects women's health.
This retrospective study mainly included patients who received continuous adjuvant anthracycline and/or taxane drug treatment during 1993-2010.
This retrospective study mainly included patients who received continuous adjuvant anthracycline and/or taxane drug treatment during 1993-2010.
The researchers identified a total of 2003 eligible patients: 1102 of them started chemotherapy within 31 days after surgery, and 901 started chemotherapy after ≥31 days.
Related research flow chart
Related research flow chartThe 5-year OS of patients who received chemotherapy for <31 or ≥31 days after surgery was similar (90% vs 91%, HR=1.
Among 250 patients with triple-negative breast cancer, those who received chemotherapy for ≥31 days had significantly lower OS than those who received chemotherapy for <31 days (HR=2.
Kaplan-Meier curve analysis of disease-free survival rate of patients
Kaplan-Meier curve analysis of disease-free survival rate of patientsAll in all, the results of the study showed that although in the entire study population, adjuvant chemotherapy for ≥31 days after surgery did not affect patients' DFS and OS, in patients with triple-negative breast cancer, chemotherapy for ≥31 days after surgery would significantly reduce The patient's 5-year OS.
Although in the entire study population, adjuvant chemotherapy for ≥31 days after surgery did not affect the patients' DFS and OS, in patients with triple-negative breast cancer, chemotherapy for ≥31 days after surgery significantly reduced the patients' 5-year OS.
org/10.
Leave a message here
